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Background: MicroRNAs (miRNAs), small noncoding RNA molecules can function as oncogenes or tumor
suppressors in tumorigenesis. Oral squamous cell carcinoma (OSCC) is one of the most prevalent cancers
worldwide with a 5-year survival rate of approximately 50%.
Methods: The expression of microRNA-99a (miR-99a) in OSCC tissues and cell lines was investigated using quantitative
reverse transcription-polymerase chain reaction (qRT-PCR) analysis. The functions of miR-99a in migration/invasion and
lung colonization were determined by transwell and tail vein injection assays, respectively. Specific targets of miR-99a
were determined by software prediction, correlation with target protein expression, and luciferase reporter assay. The
signaling pathways involved in regulation of miR-99a were investigated using the kinase inhibitors.
Results: We observed reduced levels of miR-99a, identified as one of the most downregulated miRNA in OSCC and all
tested OSCC cell lines compared to normal oral keratinocytes. Ectopic miR-99a expression in OSCC cells markedly
reduced migration and invasion in vitro as well as lung colonization in vivo. When evaluating the specific targets of
miR-99a, we found that ectopic miR-99a expression downregulates insulin-like growth factor 1 receptor (IGF1R) protein
and that the expression of miR-99a correlates negatively with IGF1R protein in OSCC cells. Insertion of the 3′UTR
of IGF1R mRNA into the 3′UTR of a reporter gene markedly reduced luciferase activity in OSCC cells expressing
miR-99a, suggesting that miR-99a reduces luciferase activity by targeting the 3′UTR of IGF1R mRNA. When evaluating
the mechanisms of miR-99a downregulation, we observed the upregulation of miR-99a expression in serum-starved
conditions and its suppression in response to insulin-like growth factor (IGF1) stimulation. Inhibitors of phosphatidylinositol
3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) kinase inhibited IGF1-induced suppression of miR-99a,
suggesting the negative regulation of miR-99a expression by IGF1R signaling.
Conclusion: Overall, results indicate that miR-99a functions as a tumor metastasis suppressor in OSCC cells and mutually
regulates IGF1R expression in a reciprocal regulation.
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Oral cancer is one of the most common cancers world-
wide with an annual estimated incidence of approxi-
mately 275 000. More than 90% of oral cancers are
squamous cell carcinomas arising in the oral cavity [1].
The initiation and progression of OSCC involve a multi-
step process of aberrant genetic events following the ac-
tion of various carcinogens, which might be derived
from the chronic use of tobacco, alcohol, and betel quid
[2]. Cigarette smoking and alcohol drinking are the
major risk factors for OSCC in western countries. In
southeast Asia, betel quid chewing and cigarette smoking
are the predominant risk factors for OSCC [2]. Currently,
the treatment of OSCC is problematic. In most countries,
the 5-year survival rate for oral cancer is approximately
50% [1], with locoregional recurrence and/or distant me-
tastasis the major causes of death in these patients [3]. To
improve the treatment outcome, elucidation of the mo-
lecular mechanisms involved in the carcinogenesis and
progression of OSCC is, therefore, needed.
In recent years, biomedical investigation has increasingly
focused on a relatively small number of microRNAs (miR-
NAs), noncoding RNAs approximately 17 to 25 nucleo-
tides in length [4]. These miRNAs are transcribed by RNA
polymerase II in hairpin structures and processed by
RNase III Drosha into long precursor miRNAs (pre-miR-
NAs) in the nucleus [4]. The precursors are then trans-
ported into the cytoplasm and processed by RNase III
Dicer to form mature miRNA, which regulates gene
expression by controlling mRNA translation and stability.
It does this through the translational repression of its tar-
get mRNA, or by increasing its degradation using an RNA
interference mechanism [4]. Evidence suggests that miR-
NAs can be functionally classified as proto-oncogenes or
tumor suppressor genes and aberrantly expressed in differ-
ent cancer types Dysregulation of these cancerous miR-
NAs is involved in tumor initiation and progression by
facilitating an inappropriate cellular program that pro-
motes uncontrolled cell proliferation, favors survival, in-
hibits differentiation, or induces invasive behavior [5-7].
Previous studies characterized microRNA-99a (miR-99a)
as a tumor suppressor in several human cancers, including
childhood adrenocortical tumors [8], prostate [9], liver
[10], head and neck [11], and oral [12] cancers. These stud-
ies showed that expression of miR-99a could reduce the
expression of a number of proto-oncogenes by targeting
their 3′ untranslated region (3′UTR) [8-13]. Several groups
further identified the downregulation of miR-99a in clinical
samples of oral or head and neck squamous cell carcinoma
(HNSCC) of different stages using miRNA microarray ana-
lysis [11,12,14-16]. However, most of the biological func-
tions of miR-99a in OSCC remain unknown.
Considering the diverse and overlapping biological func-
tions of the identified targets of miR-99a, it is possible thatan additional miR-99a target might contribute to OSCC
tumorigenesis. In this study, we identified IGF1R as a spe-
cific target of miR-99a. The IGF1R is overexpressed in sev-
eral cancers, including in OSCC tissues and cell lines
[17,18], and essential for malignant transformation and
progression [19]. In the study by Lara et al., IGF1R expres-
sion was a predictor of clinical outcome in patients with
locally advanced OSCC [20].
Insulin-like growth factor 1 receptor is a transmem-
brane tyrosine kinase receptor with a heterodimer of
α- and β-chains, and activated by its ligands insulin–like
growth factor 1 (IGF1) and insulin-like growth factor 2
(IGF2) [21]. Insulin-like growth factor 1 receptor signal-
ing pathways influence cancer cell proliferation, adhe-
sion, migration, and cell death, and are critical in tumor
cell survival and metastasis [22]. Activation of IGF1R
leads to activation of the Ras, Raf, and mitogen-activated
protein kinase (MAPK) pathway, resulting in increased
proliferation and stimulation of the phosphatidylinositol
3-kinase (PI3K) pathway, which subsequently leads to
the inhibition of apoptosis [23]. The overexpression of a
constitutively active form of IGF1R in the mouse mam-
mary gland can initiate tumorigenesis [24], whereas expres-
sion of a dominant negative IGF1R inhibits Ras-induced
cell transformation [25]. In this study, we demonstrated
that miR-99a is downregulated in OSCC tissues and cell
lines and can function as a tumor metastasis suppressor
for migration, invasion and lung colonization in OSCC
cells. Using bioinformatic prediction and luciferase re-
porter assays, we further confirmed that miR-99a nega-
tively regulates IGF1R protein levels by specifically binding
to the 3′UTR of IGF1R mRNA. We identified the negative
regulation of miR-99a expression by IGF1-induced signal-
ing and proposed a reciprocal regulation responsible for
the mutual regulation of miR-99a and IGF1R.
Results
Downregulation of miR-99a in OSCC patients and cell
lines
We examined the miRNA expression profiles of 40 pairs
of OSCC tissue specimens and their corresponding non-
tumorous epithelia, with results identifying miR-99a as
one of the most downregulated miRNAs (GSE45238).
The expression of miR-99a was reduced significantly in
OSCC samples in comparison with the adjacent noncan-
cerous tissues (Figure 1A). Twenty-eight of 40 (70%)
OSCC tissue samples exhibited a >2-fold decrease in
miR-99a expression relative to their corresponding non-
tumorous tissues (Figure 1B). These findings were con-
firmed by results from quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) analysis using 20
pairs of OSCC samples and their corresponding nontu-
morous tissues. Consistent with these data, we detected
reduced levels of miR-99a in most of the tested samples
Figure 1 Downregulation of miR-99a in OSCC tissues and cell lines. (A) MiR-99a was downregulated significantly in OSCC tissues compared
to nontumorous tissues. *** p < 0.001. (B) Microarray analysis revealed the significant downregulation of miR-99a expression in 28/40 (70%) OSCC
tissues, with a >2-fold decrease in expression in comparison with the corresponding nontumorous tissues. The relative miR-99a expression was
determined by dividing the detected signal from a tumorous tissue by that from its corresponding nontumorous tissue. (C) Validation of miR-99a
expression in 20 pairs of OSCC tissues using qRT-PCR analysis. Expression of miR-99a was normalized against an endogenous control U6. The relative
expression of miR-99a was determined by normalizing the expression of miR-99a in a tumorous tissue to that in its corresponding nontumorous tissue.
Bar, SE. (D) The relative expression of miR-99a in 16 OSCC cell lines and one HOK cell line was evaluated using qRT-PCR analysis. Expression of miR-99a
was normalized against an endogenous control U6. The relative expression of miR-99a was determined by normalizing the expression of miR-99a in
OSCC cell lines to that in HOK. Bar, SE.
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crease in miR-99a expression compared to their corre-
sponding nontumorous tissues (Figure 1C). We also
used qRT-PCR to examine the expression of miR-99a in
16 OSCC cell lines, observing reduced levels of miR-99a
in all OSCC cell lines when compared with normal hu-
man oral keratinocytes (HOK) (Figure 1D). To address
the clinical significance of downregulated miR-99a in
OSCC, we investigated the correlation between the
clinicopathological features of OSCC and miR-99a expres-
sion using 2-tailed student’s t test. We observed insignificantcorrelation between clinicopathological parameters, in-
cluding pathological stage, and tumor status (Additional
file 1: Table S1). Interestingly, the levels of miR-99a
expression displayed significantly lower in OSCC with
lymphovascular invasion than in OSCC without lympho-
vascular invasion (p = 0.0144) (Additional file 1: Table S1),
suggesting a role of miR-99a in lymphovascular invasion.
The identification of significant reductions in miR-99a ex-
pression in OSCC tissues and cell lines compared to non-
tumorous tissues and HOK cells suggested that miR-99a
has possible pathological roles in OSCC.
Figure 2 Ectopic miR-99a expression suppressed migration, invasion and lung colonization. (A) Levels of miR-99a in OEC-M1 and CGHNC9
cells with ectopic miR-99a expression (OEC-M1 miR-99a and CGHNC9 miR-99a) and their corresponding controls with lentiviral non-silencing
microRNA (OEC-M1 NS and CGHNC9 NS) were determined using qRT-PCR analysis. MiR-99a expression was normalized against an endogenous
control U6. The relative expression of miR-99a was determined by normalizing the expression of miR-99a in cells with ectopic miR-99a expression
(miR-99a) to that in control cells (NS). Bar, SE; ***p < 0.001. (B) Cell proliferation was analyzed in OEC-M1 cells with ectopic miR-99a expression
(OEC-M1 miR-99a) and controls (OEC-M1 NS). Bar, SE. (C) Cell proliferation was evaluated in CGHNC9 cells with ectopic miR-99a expression
(CGHNC9 miR-99a) and controls (CGHNC9 NS). Bar, SE. (D) The relative migration/invasion activity of OEC-M1 cells expressing miR-99a (OEC-M1
miR-99a) and controls (OEC-M1 NS). Bar, SE; * p < 0.05; ***p < 0.001. (E) The relative migration/invasion activity of CGHNC9 cells expressing miR-99a
(CGHNC9 miR-99a) and controls (CGHNC9 NS). Bar, SE; * p < 0.05; ***p < 0.001. (F) Representative lung field of nude mice after delivery via tail vein
injection of OEC-M1 cells with ectopic miR-99a expression (OEC-M1 miR-99a) or controls (OEC-M1 NS). The white arrowhead indicates tumor nodule in
the lung fields. The boxed area in the upper panel is shown at higher magnification in the lower panel. (G) Quantification of colony number/per lung
section in mice injected with miR-99a expressing OEC-M1 (OEC-M1 miR-99a) or controls (OEC-M1 NS). Bar, SE; *p < 0.05.
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colonization in OSCC cells
To further investigate the biological functions of miR-
99a, we overexpressed miR-99a in OSCC cell lines using
lentiviral infection, and then analyzed the cells using
qRT-PCR. Results indicated that ectopic miR-99a ex-
pression in OEC-M1 and CGHNC9 cells, established
from Taiwan OSCC patients, led to increased miR-99a
expression (Figure 2A) and insignificant reductions in
cell growth (Figures 2B and 2C) when compared with
their corresponding controls. Using transwell assay, we
then identified that migration and invasion activities
were reduced significantly in the OEC-M1 cells with ec-
topic miR-99a expression when compared with their
corresponding controls (Figure 2D). We observed similar
results in CGHNC9 cells with ectopic miR-99a expres-
sion (Figure 2E). To determine whether the effects of
miR-99a on migration and invasion correlated with lung
colonization, we injected OSCC cells into mice via tail
vein injection. We observed that ectopic miR-99a expres-
sion led to decreased colony number of tumor nodules in
the lungs (2.33 ± 0.76 versus 5.83 ± 0.87/per lung section
for vector control) (Figures 2F and 2G). These data in-
dicated that miR-99a functions as a tumor metastasis
suppressor of migration, invasion and lung colonization in
OSCC cells.
MiR-99a does not influence cell morphology and subtly
affect the expression of epithelial-mensenchymal transi-
tion (EMT)-related proteins and metalloproteinases
Tumor cell migration is often associated with reorga-
nization of the actin cytoskeleton and the occurrence of
an EMT. We thus evaluated the effects of miR-99a on
cell morphology and the EMT process. Analysis of cell
morphology using light microscopy and fluorescent con-
focal microscope by phalloidin staining and immuno-
flurescence with anti-α-tubulin, E-cadherin and focal
adhesion kinase (FAK) did not reveal any gross dif-
ferences between miR-99a expressing cells and vector
controls (Figure 3A and Additional file 2: Figure S1).
Furthermore, results from immunoblot analysis showed
that ectopic miR-99a expression slightly increased the
expression of α-catenin, an epithelial protein in OEC-
M1 cells, and reduced the expression of N-cadherin, a
mesenchymal marker in CGHNC9 cells (Figure 3B).
Ectopic miR-99a expression partially reduced the levels
of EMT-related transcription factors, such as Snail, and
Slug in CGHNC9 cells (Figure 3C). The expression of
metalloproteinase 2 (MMP2) and 9 (MMP9) did not
show a markedly reduction in cells with ectopic miR-99a
expression (Figure 3D). Ectopic miR-99a expression,
therefore, did not markedly influence the expression of
the EMT-related proteins and transcription factors as
well as metalloproteinases.MiR-99a negatively regulates IGF1R protein levels and
reduces IGF1R signaling
We further investigated if the specific binding of miR-99a
caused the miR-99a-mediated reductions in expression of
EMT-related protein, transcription and metalloproteinase
by evaluating the correlation between miR-99a expression
and the candidate gene expression using miRWalk for pre-
diction (Additional file 1: Table S2) [26]. Results excluded
this possibility and indicated that the components of the
IGF1R signaling pathway, including mTOR and IGF1R,
could be the potential targets of miR-99a (Additional
file 1: Table S2). When analyzing the human sequences for
interspecies homology, we observed that the miR-99a tar-
get sequences of IGF1R or mTOR are highly conserved
among species (Figure 4A). Using gene expression analysis
(GSE37991) of Taiwan OSCC tissues, we detected a >2-
fold increase in IGF1R mRNA in 22/40 OSCC tissue
samples in comparison with their corresponding adjacent
nontumorous tissues (Additional file 3: Figure S2A). By
immunoblot assay, we demonstrated up-regulated IGF1R
expression in most of OSCC cells in comparison with
HOK cells (Additional file 3: Figure S2B). The data indi-
cated that IGF1R might play an important role in oral
tumorigenesis. We then used Pearson correlation to deter-
mine whether IGF1R and mTOR are the possible targets
of miR-99a, comparing miR-99a expression with the levels
of IGF1R and mTOR protein in OSCC cells. We observed
a significant negative correlation between miR-99a expres-
sion and levels of IGF1R protein (r = −0.747, p = 0.0207)
(Figure 4B) but no such correlation between miR-99a
expression and levels of mTOR protein in OSCC cells
(r = −0.1164, p = 0.7655) (Figure 4C). This suggested the
inverse correlation between the expression of miR-99a
and that of IGF1R protein. To verify the targets of miR-
99a, we investigated the mRNA and protein levels of
IGF1R and mTOR in miR-99a expressing OSCC cells
(Additional file 4: Figure S3 and Figure 4D). Results from
Western blot analysis further showed that ectopic miR-
99a expression decreased IGF1R expression, but not
mTOR expression in OSCC cells (Figure 4D). To deter-
mine whether IGF1R mRNA is the specific binding target
of miR-99a, we used the clones of the human IGF1R 3′
UTR fragment containing the wild type or mutant miR-
99a binding sequence in the region downstream of the
Renilla luciferase reporter gene. In OEC-M1 cells with ec-
topic miR-99a expression, the luciferase activity of cells
expressing wild type IGF1R 3′UTR was reduced 0.75 ±
0.03-fold in comparison with cells expressing the mutant
seed region of miR-99a in the IGF1R 3′UTR (Figure 4E).
However, in OEC-M1 control cells with low miR-99a ex-
pression, the luciferase activity of cells expressing wild
type or mutant IGF1R 3′UTR remained unchanged. These
data indicated that miR-99a negatively regulates IGF1R
expression by directly targeting the 3′UTR of IGF1R
Figure 3 (See legend on next page.)
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Figure 3 Overexpression of miR-99a did not influence cell morphology and subtly affected the expression of EMT-related proteins and
metalloproteinases. (A) Ectopic miR-99a expression had no obvious effects on cell morphology when OEC-M1 and CGHNC9 cells with ectopic
miR-99a expression (OEC-M1 miR-99a and CGHNC9 miR-99a) compared with their corresponding controls with lentiviral non-silencing microRNA
(OEC-M1 NS and CGHNC9 NS) using phase contrast microscopy with 100× magnification (left panel). Cytoskeleton F-actin proteins were
stained with Alex Fluro 488 phalloidin and viewed under fluorescence microscope with 630× magnification (right panel, shown in grey
mode). (B) Immunoblot analysis of epithelial (E-cadherin and α-catenin) and mesenchymal (N-cadherin and vimentin) proteins in OEC-M1
NS, OEC-M1 miR-99a, CGHNC9 NS, and CGHNC9 miR-99a cells. (C) Immunoblot analysis of EMT-related transcription factors, including Snail,
Slug, and Twist proteins in OEC-M1 NS, OEC-M1 miR-99a, CGHNC9 NS and CGHNC9 miR-99a cells. (D) Immunoblot analysis of pro- and
active forms of metalloproteinase 2 (MMP2) and metalloproteinase 9 (MMP9) in OEC-M1 NS, OEC-M1 miR-99a, CGHNC9 NS, and CGHNC9
miR-99a cells. The protein levels were normalized against an internal control β-actin or α-tubulin. Ratios were determined by dividing the
normalized protein levels in miR-99a expressing cells with that in control cells. The means of ratio in the graphs were measured by averaging the ratios
from independent blots. Bar, SE; *p < 0.05.
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whether ectopic IGF1R expression was sufficient to rescue
the miR-99a-mediated inhibition of migration and inva-
sion, IGF1R was transiently expressed in miR-99a express-
ing OEC-M1 cells and confirmed by immunoblot assay
(Additional file 5: Figure S4A). We observed that the mi-
gration and invasion activities were rescued by ectopic
IGF1R expression in miR-99a expressing OEC-M1 cells,
indicating that IGF1R was involved in miR-99a-mediated
reduction of migration and invasion (Additional file 5:
Figure S4B).
The IGF1R signaling pathway negatively regulates miR-
99a expression
To elucidate the mechanisms underlying the downregu-
lation of miR-99a, we first investigated the possibility of
genetic methylation, which typically occurs at CpG sites
and inactivates gene transcription. We computationally
mapped the CpG islands upstream of the miR-99a gene
but detected no CpG-enriched region (data not shown).
We then treated 3 OSCC cell lines that express low
levels of miR-99a with 5-aza-deoxygcitidine (5-Aza-dC),
a methylation inhibitor. However, this treatment did not
increase miR-99a expression (Figure 5A). These data
suggested that promoter methylation did not cause the
downregulation of miR-99a.
The levels of total and phosphorylated IGF1R protein
reduced in serum starvation, suggesting the possibility
of upregulation of miR-99a in serum-free conditions
(Figure 5B). To verify this, we analyzed the levels of
miR-99a in cells cultured in serum-free medium for dif-
ferent duration, observing that a 1.7-fold increase of
miR-99a expression was detected in cells subjected to
serum starvation for 24 hours and the expression of
miR-99a increased significantly in serum starvation in a
time-dependent manner (Figure 5C). Collectively, these
data suggested the upregulation of miR-99a expression
following the removal of supplied growth factors.
Following the retreatment of cells with serum or IGF1
after serum starvation, we observed reduced expression
of miR-99a compared with cells in serum-free conditions(Figure 6A). This suggested that serum or IGF1 regulates
the expression of miR-99a. Results from immunoblot
analysis indicated that IGF1R protein was reduced in
serum starvation conditions, whereas IGF1R protein was
significantly increased following serum or IGF1 treat-
ment (Figure 6B). These data indicated the negative
regulation of miR-99a expression by serum or IGF1
stimulation. To verify whether the regulation of miR-
99a is mediated by activation of IGF1R signaling path-
way, the data showed that cells displayed the decreased
phosphorylation levels of AKT and MAPK upon treat-
ment with the LY294002 and PD98059 inhibitors for
downstream of IGF1R signaling pathways, PI3K and
MAPK kinase, respectively (Additional file 6: Figure S5).
We found that the inhibitors LY294002 and PD98059
eliminated IGF1-induced downregulation of miR-99a
in a dose-dependent manner (Figures 6C and 6D).
Additionally, levels of miR-99a were decreased in non-
silencing miRNA expressing OEC-M1 cells with ectopic
expression of IGF1R (Additional file 5: Figure S4C).
Overall, these findings suggested the negative regulation
of miR-99a expression by the IGF1R signaling pathway
and the presence of a reciprocal regulation for the
mutual regulation of miR-99a expression and IGF1R
protein levels.
Discussion
Previous studies used miRNA microarray and qRT-PCR
analyses to characterize the miRNA expression profiles
in oral cancer cell lines and clinical samples of different
stages [27,28]. Their findings suggested the dysregulation
of miRNAs in the initiation and progression of oral can-
cers. Similar to the results from a study by Wong et al.
[14], our data showed that miR-99a is frequently down-
regulated in OSCC cell lines and tissues, especially in
OSCC patients with lymphovascular invasion (Figure 1
and Additional file 1: Table S1). This suggested that
the downregulation of miR-99a might play a critical role
in invasion and metastasis of OSCC and supported evi-
dence that ectopic miR-99a expression inhibits cell
migration, invasion and lung colonization in OSCC cells
Figure 4 MiR-99a targeted IGF1R in OSCC cells. (A) Comparison of nucleotides in the miR-99a seed sequence and the targets, mTOR (upper panel)
and IGF1R (lower panel), within the 3′UTR among species. (B) Significant negative correlation between the expression of miR-99a and IGF1R protein in
OSCC cell lines (r =−0.747, p = 0.0207) by Pearson correlation. Average amounts of IGF1R protein were determined in two independent blots. *p < 0.05.
(C) No significant correlation between expression of miR-99a and mTOR protein in OSCC cell lines by Pearson correlation (r =−0.1164, p = 0.7655). Average
amounts of mTOR proteins were determined in two independent blots. (D) Immunoblot analysis of IGF1R and mTOR expression in OEC-M1
and SCC15 cells with ectopic miR-99a expression (OEC-M1 miR-99a and SCC15 miR-99a) or non-silencing microRNA expressing controls
(OEC-M1 NS and SCC15 NS). The protein levels were normalized against an internal control α-tubulin. Ratios were determined by dividing
the normalized protein levels in miR-99a expressing cells with that in non-silencing microRNA expressing controls. The means in the lower
graph were measured by averaging the ratios from independent blots. Bar, SE; *p < 0.05. (E) Ectopic miR-99a expression suppressed the
expression of the Renilla luciferase reporter gene containing the wild type miR-99a binding sequence in IGF1R 3′UTR (IGF1R 3′UTR) in
OEC-M1 miR-99a cells. The luciferase activity of the construct with the deleted miR-99a binding site for IGF1R 3′UTR (ΔIGF1R 3′UTR) was
assigned as 1. Bar, SE; *p < 0.05.
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pression in hepatocellular carcinoma (HCC) tissues was
associated with worse prognosis in HCC patients [10].
However, in this study, we observed insignificant correl-
ation between miR-99a expression and most of clinico-
pathological parameters (Additional file 1: Table S1).
The biological roles of miR-99a in oral tumorigenesis
remain unclear. Previous studies described that ectopic
miR-99a expression slowed keratinocyte growth and livercancer cell growth by blocking the cell cycle at the G1/S
transition [10,29]. In OEC-M1 and CGHNC9 cells,
ectopic miR-99a expression had no significant effects
on cell growth (Figures 2B and C), cell cycle (Additional
file 7: Figure S6A) and cell morphology (Figure 3A and
Additional file 2: Figure S1) even though ectopic expres-
sion of miR-99a did subtly affect the expression of cell
cycle-related molecules (Additional file 7: Figure S6B) and
EMT-related proteins (Figure 3). However, ectopic miR-
Figure 5 Regulation of miR-99a expression in different culture conditions. (A) The levels of miR-99a expression in OEC-M1, TW2.6, and
HSC3 oral cancer cells treated with 5 μM 5-Aza-dC for 96 hours were determined using qRT-PCR analysis. Expression of miR-99a was normalized
against an endogenous control U6. Data from 5-Aza-dC-treated OSCC cell lines were normalized to those from untreated controls. (B) Immunoblot
analysis revealed reduced levels of total and phosphorylated IGF1R protein in non-silencing microRNA expressing controls (OEC-M1 NS) with
serum starvation. Ratios were determined by dividing the protein levels in serum-starved cells with that in complete medium (CM). The means
in the lower panel were measured by averaging the ratios from independent blots. Bar, SE; *p < 0.05. (C) MiR-99a expression increased in serum
starvation in a time-dependent manner. Expression of miR-99a was normalized against an endogenous control U6. The relative expression of
miR-99a was determined by normalizing the expression of miR-99a in OEC-M1 NS cells in serum starvation to that in complete medium (CM).
Bar, SE; **p < 0.01.
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colonization (Figures 2D-G). These observations suggested
that the diverse biological functions of miR-99a may be
cell type- and context- dependent. Because of low miR-
99a expression in all tested OSCC cells, we were unable to
observe any significant knockdown of miR-99a in OSCC
cells in response to anti-miR-99a expression (data not
shown).
With bioinformatic prediction and experimental valid-
ation using microarray and polyribosomal loading analysis,
Sun et al. identified that IGF1R and mTOR are the direct
targets of miR-99a [9]. In our study, the expression of
miR-99a correlated inversely with IGF1R, but not mTOR
protein expression (Figures 4B and 4C). Ectopic expres-
sion of miR-99a decreased the levels of IGF1R protein
(Figure 4D and Additional file 4: Figure S3), suggestingthat IGF1R, but not mTOR, is a specific target of miR-99a
in OSCC cells. However, it remains possible that miR-99a
might functionally target mTOR in other cell types or in
different biological systems [12]. It is, therefore, possible
that other molecules or signaling pathways influenced by
miR-99a could be involved in OSCC pathogenesis, and
that some of them have yet to be identified.
Insulin-like growth factor 1 receptor is overexpressed
in several malignancies and plays a crucial role in pro-
moting cell proliferation and metastasis [30]. Our re-
sults demonstrated that miR-99a expression decreases
IGF1R protein levels by directly targeting the 3′UTR of
IGF1R mRNA (Figure 4E). Previous studies have identi-
fied that IGF1R is also a specific target of miR-145 in
colon cancer cells [31], miR-122 in liver cancers [32],
miR-7 in tongue squamous cell carcinoma cells [28],
Figure 6 Negative regulation of miR-99a expression by the IGF1R signaling pathway. (A) Downregulation of miR-99a in response to IGF1
treatment. After serum starvation, cells were treated with vehicle, 10% FBS or 10 nM IGF1. (B) Immunoblot analysis revealed increased levels of
IGF1R protein following IGF1-induced downregulation of miR-99a. After serum starvation, cells were treated with vehicle, 10% FBS or 10 nM IGF1.
The protein levels were normalized against an internal control α-tubulin. Ratios were determined by dividing the normalized protein levels in
OEC-M1 cells with different conditions to that in complete medium (CM). The means in the lower panel were measured by averaging the ratios
from independent blots. (C) The PI3K inhibitor LY294002 and (D) MAPK kinase inhibitor PD98059 suppressed the IGF1-induced downregulation of
miR-99a. After serum starvation, cells were treated with vehicle, 10 nM IGF1, or combination of LY294002/PD98059 and IGF1. Expression of miR-99a
was normalized against an endogenous control U6. The relative expression of miR-99a was determined by normalizing the expression of miR-99a in
OEC-M1 cells in different conditions to that in cells in complete medium (CM). Bar, SE; *p < 0.05; **p < 0.01; ***p < 0.001. (E) Proposed model of the
relationship between the activation of the IGF1R signaling pathway and miR-99a expression. The activation of the IGF1R signaling pathway initiated the
inhibitory signal leading to decreased miR-99a expression. Following the suppression of the IGF1R signaling pathway by inhibitors, or its silencing by
the removal of stimulation, we observed increased miR-99a expression because of the removal of the inhibitory signal. This reciprocal regulation of
miR-99a and IGF1R signaling augmented the activation of the IGF1R signaling pathway in response to IGF1 stimulation and accelerated its inactivation
following the removal of stimulation.
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and let-7c in regulation of glucose metabolism [34]. A
recent study showed that the administration of tumor-
suppressive miRNA to mice could effectively suppress
tumorigenesis in liver cancer without causing toxicity[35]. This indicated the possibility of using miRNA to
target IGF1R in cancer therapy.
Although previous studies identified reduced miR-99a
expression in several types of tumors [8,9,11,12,14,36-38],
the detailed mechanisms underlying its repression remain
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including DNA methylation and histone modification [39],
chromosome deficiency [40], and transcriptional regulation
[41] can influence the downregulation of miRNA. Yamada
et al. showed that the gene encoding miR-99a, located in
chromosome 21q21, is frequently deleted in lung cancers
[36]. In this study, we examined 40 paired tissue samples
from OSCC patients for chromosome deletions using array
comparative genomic hybridization and failed to identify
any obvious deletion in chromosome 21q21 (data not
shown). We then considered the hypermethylation of the
CpG islands surrounding miRNA genes as markers for the
investigation of epigenetically silenced miRNAs. However,
reactivated expression of miR-99a was undetectable in oral
cancer cells after treatment with 5-Aza-dC (Figure 5A).
Similarly, Li et al. suggested that there was little evidence
of the contribution of methylation to downregulation of
miR-99a [10]. These findings indicated that promoter
methylation did not cause the downregulation of miR-99a.
Reduced endogenous miR-99a in OSCC cells retreated
with IGF1 after serum starvation (Figure 6A), increased
miR-99a expression in cells treated with PI3K or MAPK
kinase inhibitors (Figures 6C and 6D), and a reduced
level of miR-99a in OSCC cells provided further evi-
dence of the regulation of levels of miR-99a by IGF1R
signaling. We proposed a model to describe the combin-
ing of the functions of miR-99a and IGF1R to achieve a
maximal effect in OSCC cells in response to IGF1R acti-
vation (Figure 6E). Activation of the IGF1R signaling
pathway initiated the inhibitory signal for miR-99a ex-
pression. Decreased miR-99a expression then increased
the levels of IGF1R protein. Inhibition of the IGF1R sig-
naling pathway by depletion of growth factors or specific
chemical inhibitors increased miR-99a expression be-
cause of the loss of the inhibitory signal. This then re-
duced the levels of IGF1R protein. This reciprocal
regulation, therefore, maximizes the activation of the
IGF1R signaling pathway in OSCC cells in response to
IGF1 stimulation. Due to tumor heterogeneity, however,
our results indicated a reciprocal regulation that mutu-
ally regulates the levels of miR-99a and IGF1R in a part
of OSCC cells. Different from our hypothesis, Lerman
et al. described that the activation of IGF1 signaling in-
creased the expression of miR-99a, which then repressed
the expression of IGF1R in psoriatic skin [29]. Huang
et al. showed that IGF1 significantly accelerated the up-
regulation of miR-133, which targeted IGF1R during
skeletal myogenesis [42]. Both studies described the
reciprocal regulation of miRNA and IGF1R during pro-
liferation and differentiation in normal tissues. Collect-
ively, this reciprocal regulation is potentially involved
in a number of genetic pathways involving miRNA, and
might enhance the functionality and robustness of gene
networks [43]. Other previous studies described similarfindings involved in the regulation of let-7 g and lectin-
like oxidized LDL receptor-1 (LOX-1) [44]; let-7 and
Fas [45]; ZEB1-SIP and the miR-200 family [46].
The mechanisms for the negative regulation of miR-99a
by the IGF1R signaling pathway remain unclear. Several
studies described the positive correlation between the ex-
pression of mature miR-99a and primary miR-99a and that
of their host gene C21orf34/LINC00478 in liver and pros-
tate cancer tissues, suggesting the possible cotranscription
of miR-99a with C21orf34 [10,47]. Willimott et al. re-
ported that stromal cell contact induced the expression of
the miRNA cluster miR-99a/let-7c/miR-125b, indicating
the involvement of transcriptional regulation in the induc-
tion of this miRNA cluster [48]. Future investigation to
evaluate the possible promoter regions and to identify the
transcription factors binding to the region upstream of the
miR-99a gene is, therefore, warranted.
Collectively, we demonstrated that miR-99a is fre-
quently down-regulated and functions as a tumor metas-
tasis suppressor in OSCC cells. Also, miR-99a mutually
regulates its own target, IGF1R expression within a re-
ciprocal regulation, suggesting that the possibility of
miR-99a for targeting IGF1R in cancer therapy.
Materials and methods
Clinical samples and patient characteristics
Paired tumor specimens and their adjacent nontumorous
epithelia were derived from 40 primary OSCC patients who
received curative surgery from 2002 to 2009 at National
Cheng Kung University Hospital. Fresh frozen tissues were
preserved in liquid nitrogen until use. Clinical parameters,
including age, sex, social history, pathological features, and
TMN stage, were retrospectively collected by reviewing
patients’ charts. The study protocol was approved by the
Institutional Human Experiment and Ethics Committee.
Informed consent was obtained from each patient.
Oral squamous cell carcinoma cell lines
Human oral keratinocytes (HOK) were purchased from
ScienCell Research Laboratories and cultured in an oral
keratinocyte medium (OKM; ScienCell Research Labo-
ratories, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. OSCC cell lines, including CGHNC9
[28], OC3 [49], OEC-M1 [50], TW2.6 [51], FaDu [52], KB
[53], SCC-4, SCC15 [54], SCC9, SCC25 [55], UT-MUC-1
[56], YD-15 [57], DOK [58], Tu183 [59], UMSCC1 [60]
and HSC3 [61], were cultured at 37°C in a 5% CO2 atmos-
phere within 3 months of resuscitation from the frozen
aliquots, with lower than 20 passages in each experiment.
Quantification of miRNA
Total RNA molecules were polyadenylated and reverse
transcribed using poly (A) polymerase and MMLV
reverse transcriptase in a Mir-X™ miRNA First-Strand
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the manufacturer’s manual. Real-time quantitative poly-
merase chain reactions were performed using a Fast
SYBR® Green Master Mix (Applied Biosystems, Foster
City, CA, USA) for amplification. Specific miRNA se-
quences in the cDNA were quantified using miRNA-
specific sequences as 5′ primers. The forward primer used
for miR-99a was 5′ AACCCGTAGATCCGATCTTGTG.
The U6 was used as a reference for miRNA quantification
and was supplied in the kit. All amplifications were
performed in triplicate and values were normalized to
an endogenous control U6. The relative expression of
miRNA was normalized to that of the control in each
experiment.Immunoblot analysis
Immunoblot assays were performed as described pre-
viously [62]. Primary antibodies were used as follo
wed: anti-E-cadherin (610182, BD, San Jose, CA, USA),
anti-α-catenin (610193, BD), anti-N-cadherin (610920, BD),
anti-Vimentin (MS-129-P0, Thermo Scientific, Cheshire,
UK), anti-Twist (sc-15393, Santa Cruz, Santa Cruz, CA,
USA), anti-Snail (3895, Cell Signaling, Danvers, MA,
USA), anti-Slug (AP2053a, Abgent, San Diego, CA,
USA), anti-MMP2 (#4022, Cell Signaling), anti-MMP9
(#2551-1, Epitomics, Burlingame, CA, USA), anti-phos
pho-mTOR (Ser2448) (#5536, Cell Signaling), anti-
mTOR (#2972, Cell Signaling), anti-phospho-IGF1 Re-
ceptor β (Tyr980) (#4568, Cell Signaling), anti-IGF1
Receptor β (#3018, Cell Signaling), anti-p21 (#2946,
Cell Signaling), anti-p27 (#2552, Cell Signaling), anti-
cyclin D1 (#2926, Cell Signaling), anti-cyclin E (sc-247,
Santa Cruz), anti-β-actin (sc-1615, Santa Cruz) and
anti-α-tubulin (MS-581-P0, Thermo Scientific). Pro-
tein levels were determined by measuring the intensity
of bands on the blots using Image J (National Insti-
tutes of Health, Bethesda, Maryland, USA). Protein
levels were normalized against an internal control
β-actin or α-tubulin. The ratio was determined by div-
iding the normalized protein levels in expressing cells
with that in control cells. The mean of ratio was ob-
tained by averaging the ratios from several independ-
ent blots.Cell proliferation
Cell proliferation was measured using 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
assay as described previously [63]. 103 cells were seeded
onto 96-well plate and measured their growth by Cell-
Titer 96 Aqueous Non-Radioactive Cell Proliferation
assay (Promega, Madison, WI, USA) for 4–5 days ac-
cording to the manufacturer’s instructions. The prolifer-
ation curves were determined by calculating the meanvalue of absorbance measurement at 490 nm using a
96-well plate reader.
Migration and invasion assay
Migration and invasion assays were performed using
transwells as described previously [62]. Briefly, cells in
0.5 mL of serum-free medium were plated into the inserts
(Matrigel-coated inserts for invasion assay). Inserts were
placed in wells with 0.75 mL of complete medium con-
taining 10% FBS as a chemoattractant. After culture for 20
to 24 hours at 37°C, cells were fixed with methanol for
8 min and stained with Giemsa regent (Sigma, St Louis,
MO, USA). Cells on the upper sides of the inserts were re-
moved with a cotton swab, and the insert membranes
were cut and mounted on glass slides. The numbers of mi-
grated or invaded cells on the membranes were deter-
mined by counting the cell numbers in the field at 100X
magnification under light-field microscope. The relative
migration/invasion activity was measured by normalizing
the mean of total migrated/invaded cells per insert in
overexpressing cells to that in the corresponding controls.
The data shown represent the average of at least 3 re-
peated experiments.
Lung colonization assay
Lung colonization assay was performed as described previ-
ously [63]. All animal studies were followed by the guide-
lines for the Care and Use of Laboratory Animals of
National Health Research Institutes, Taiwan. The protocol
was approved by the Institutional Animal care and Use
Committee of National Health Research Institutes (Proto-
col No: NHRI-IACUC-100047-A). All efforts were made to
minimize suffering. Briefly, 105 cells suspended in phos-
phate buffered saline (PBS) were injected into nude mice
(National Laboratory Animal Center, Taiwan) via tail vein
injection. The whole lungs were harvested for paraffin
embedding, sectioning, and histological examination after
H&E staining (Pathology Core, National Health Research
Institutes, Taiwan). 6 animals were included in each group.
The number of tumor nodules in every lung section was
counted under the light-field microscope. The colony num-
ber/per lung section was determined by averaging the num-
bers of tumor nodules from independent lung sections.
Immunofluorescence
Cultured cells on slips were fixed and followed the pro-
tocols as previous described [62]. After incubation with
Alexa Fluro 488 phalloidin (1:200, Molecular Probes,
Ungene, OR, USA), anti-β-tubulin (MS-581-P0, Thermo
Scientific), anti-E-cadherin (610182, BD) and anti-FAK
(sc-557, Santa Cruz), the slips were mounted with anti-
fade onto the slides and viewed under a fluorescence
confocal microscope.
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The expression construct of miR-99a and non-silencing
microRNA were kindly donated by Dr Michael Hsiao,
Academic Sinica, Taiwan and transfected into the packaging
cell line 293FT, along with pMD.G and pCMVΔR8.91 plas-
mids, using the Polyjet transfection reagent (SignaGen Lab,
Ijamesville, MA, USA). After 48-hour incubation, viral su-
pernatants were transferred to target cells and infected cells
were cultured in the presence of different concentrations of
puromycin (Calbiochem, La Jolla, CA, USA) depending on
the cell lines.
Luciferase reporter assay
The IGF1R (nucleotides 9543 to 9833) 3′UTR sequence
(IGF1R 3′UTR) and deletions in the 3′UTR-predicted
miR-99a binding sites (ΔIGF1R 3′UTR) were cloned in
psiCHECK-2 vector (Promega) and donated by Dr Enzo
Lalli [8]. The OEC-M1 cells with ectopic miR-99a
(OEC-M1 miR-99a) or non-silencing microRNA ex-
pression (OEC-M1 NS) were transfected in 6-well
plates according to the manufacturer’s protocol. Rellina
and firefly luciferase assays were performed using the
Dual-Luciferase Reporter® Assay System (Promega),
using a luminometer for measurement of luminescence.
In each sample, the luciferase activity was determined
by normalizing the Renilla luciferase activity to the
firefly luciferase activity. The relative luciferase activity
was determined by normalizing the activity in cells with
wild type 3′UTR expression (IGF1R 3′UTR) to that in
cells with the mutant 3′UTR (ΔIGF1R 3′UTR). Experi-
ments for each construct were repeated 2 to 4 times.
Transient expression of Insulin-like growth factor I
receptor
Expression construct of IGF1R was kindly obtained from
Dr. Lu-Hai Wang, National Health Research Institutes,
Taiwan. The plasmids were transiently transfected into
cells using the Polyjet transfection reagent (SignaGen
Lab). After 48-hour incubation, cells were collected to
perform the subsequent experiments.
Prediction of miR-99a targets
Using miRWalk (http://www.umm.uni-heidelberg.de/apps/
zmf/mirwalk/), a comprehensive database with eight estab-
lished programs, including DIANA-microT (version 3.0),
miRanda (August 2010), miRDB (April 2009), PicTar
(March 2007), PITA (August 2008), RNA22 (May 2008),
RNAhybrid (version 2.1) and Targetscan (version 5.1),
miR-99a targets were predicted in 10 datasets (DIANA-
mT, miRanda, miRDB, miRwalk, RNAhybrid, PICTAR4,
PICTAR5, PITA, RNA22, TargetScan) for binding sites on
3′UTR of mRNA. For correlations, the expression of miR-
99a and interested mRNA was analyzed in 40 pairs of
OSCC patients (GSE37991) using Pearson correlation.Drug treatment
Cells were seeded and treated with 5-Aza-dC (5 μM;
Sigma). After incubating for 96 hours with a change of
culture medium every 24 hours, cells were collected for
further analysis.
Cells were seeded overnight and refreshed with serum-
free medium, then subjected to serum starvation for 12
hours. After starvation, cells were treated with vehicle,
10% fetal bovine serum (FBS) or 10 nM IGF1 (Sigma)
for different durations. For experiments involving inhib-
ition of signaling pathways, cells were cultured in the
presence of PD98059 (Sigma) or LY294002 (Sigma), spe-
cific inhibitors of MAPK kinase and PI3K, respectively,
for 1 hour prior to IGF1 stimulation.
Statistical analysis
Data are presented as the mean ± standard error of the
mean (SE) from at least 2 independent experiments. For
comparisons between 2 groups, the differences between
the groups were analyzed using 2-tailed student’s t test.
Linear regression, Pearson correlation, and Spearman
correlation were used to evaluate the correlation be-
tween 2 variants. Analysis was performed using Graph-
Pad Prism version 5.01 (GraphPad Software, La Jolla,
CA, USA). For all comparisons, p < 0.05 was considered
statistically significant.
Additional files
Additional file 1: Table S1. Correlation between clinical parameters
and relative expression of miR-99a in 40 oral squamous cell carcinoma
(OSCC) patients#. Table S2. Prediction of candidate targets of miR-99a by
miRWalk and correlations between miR-99a expression and candidate
gene expression in 40 pairs of oral squamous cell carcinoma (OSCC)
(GSE37991) by Pearson correlation.
Additional file 2: Figure S1. Over-expression of miR-99a did not change
cell morphology. (A) Ectopic miR-99a did not change cell morphology in
miR-99a expressing OEC-M1 (OEC-M1 miR-99a) and CGHNC9 (CGHNC9
miR-99a) cells when compared with their non-silencing microRNA expressing
controls, OEC-M1 NS and CGHNC9 NS under phase contrast microscopy
with 400X magnification, respectively. (B) Immunofluorescence using
anti-α-tubulin, (C) anti-E-cadherin and (D) anti-focal adherin kinase (FAK)
showed similar patterns in OEC-M1 (OEC-M1 NS and OEC-M1 miR-99a)
and CGHNC9 (CGHNC9 NS and CGHNC9 miR-99a) cells under fluorescent
confocal microscope with 630X magnification (shown in grey mode).
Additional file 3: Figure S2. Expression of IGF1/IGFR1 in OSCC tissues
and cells. (A) The level of IGF1R mRNA was up-regulated in 22/40 (55%)
of OSCC tissues with >2-fold increase by microarray analysis when
compared with their corresponding nontumorous parts. Up-regulated IGF1
mRNA was not detectable in 40 pairs of OSCC tissues. (B) Immunoblot assay
for detection of IGF1R protein in two independent batches of HOK and
OSCC cells (upper panel). The protein levels were normalized against an
internal control β-actin. Ratios were determined by dividing the normalized
protein levels in OSCC cells with that in HOK cells. The mean of ratio in the
graphs was measured by averaging the ratios from two independent blots
(lower panel). Bar, SE.
Additional file 4: Figure S3. Qunatification of IGF1R and mTOR mRNA
in miR-99a expressing OSCC cells. Quantitative RT-PCR demonstrated the
relative mRNA levels for IGF1R and mTOR in OEC-M1 and SCC15 cells
with ectopic miR-99a expression (OEC-M1 miR-99a and SCC15 miR-99a)
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All amplifications were normalized to an endogenous β-actin control. The
relative expression of mRNA in miR-99a expressing cells was normalized to
that in non-silencing microRNA expressing controls. Bar, SE; ***, p < 0.001.
Additional file 5: Figure S4. Figure S4 IGF1R rescued the inhibition of
migration and invasion in miR-99a expressing OEC-M1 cells. (A) Protein
levels of IGF1R expression were determined by Western blot in miR-99a
expressing OEC-M1 (OEC-M1 miR-99a) cells and non-silencing microRNA
expressing controls (OEC-M1 NS) with ectopic IGF1R expression. α-tubulin
served as a loading control. (B) Representative data showed the relative
migration/invasion activity of OEC-M1 NS and OEC-M1 miR-99a cells
expressing IGF1R (OEC-M1 NS/IGF1R and OEC-M1 miR-99a/IGF1R) and
their vector controls (OEC-M1 NS/VC and OEC-M1 miR-99a/VC). The relative
migration/invasion activity was defined by normalizing the mean of migrated
or invaded cells/per field in cells expressing IGF1R to that in OEC-M1 NS/VC.
Bar, SE; *p < 0.1; ***p < 0.001. (C) Levels of miR-99a were determined by
qRT-PCR in OEC-M1 NS cells with ectopic IGF1R expression. MiR-99a
expression was normalized against an endogenous control U6. The relative
expression of miR-99a was presented by normalizing miR-99a expression in
OEC-M1 NS cells with ectopic IGF1R expression (OEC-M1 NS/IGF1R) to that
in the controls (OEC-M1 NS/VC). Bar, SE; *** p < 0.001.
Additional file 6: Figure S5. Activation of AKT and MAPK by IGF1
stimulation was inhibited upon treatment with the PI3K inhibitor
LY294002 and MAPK kinase inhibitor PD98059, respectively. After serum
starvation, cells were treated with vehicle, 10 nM IGF1, or combination of
LY294002/PD98059 and IGF1. Immunoblot assay showed that levels of
phosphorylated AKT and MAPK in IGF1-stimulated OEC-M1 cells were
inhibited upon treatment with LY294002 and PD98059, respectively.
Additional file 7: Figure S6. Ectopic miR-99a expression did not change
cell cycle but subtly affected the expression of cell cycle-related proteins. (A)
Ectopic miR-99a expression did not change the cell cycle in OEC-M1 and
CGHNC9 cells using propidium iodide staining. (B) Immunoblot analysis
of cell cycle-related molecules, including cyclin D, cyclin E, p21 and p27 in
OEC-M1 and CGHNC9 cells with ectopic miR-99a expression (OEC-M1 miR-99a
and CGHNC9 miR-99a) or non-silencing microRNA expressing controls
(OEC-M1 NS and CGHNC9 NS). α-tubulin served as an internal control.
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